Botox for Chronic Migraine: Mechanism, Efficacy, and Practical Considerations

OnabotulinumtoxinA (Botox) is FDA-approved for chronic migraine (≥15 headache days/month, ≥8 migraine days). It reduces frequency and severity in appropriately selected patients.

Mechanism

  • Inhibits peripheral release of CGRP, glutamate, substance P from trigeminal nerve endings.
  • Reduces central sensitization via decreased afferent input.
  • May modulate muscle spindle feedback (cervical/pericranial).
  • Not primarily via cosmetic muscle relaxation (fixed-dose, fixed-site protocol).

PREEMPT Protocol (Evidence-Based)

  • 155–195 Units across 31–39 injection sites: frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinals, trapezius.
  • Every 12 weeks. Onset: 2–4 weeks; peak effect cycle 2–3.

Efficacy

  • ≥50% reduction in headache days: ~48% (vs. 25% placebo) at week 24.
  • Mean reduction: 8–9 fewer headache days/month.
  • Improves HIT-6, MIDAS, MSQ scores.
  • Less effective for episodic migraine or tension-type headache.

Side Effects

  • Neck pain, muscle weakness, injection site pain, eyelid ptosis (rare, technique-dependent)
  • Dysphagia (rare; avoid excessive trapezius dose)
  • No systemic cognitive/sedative effects.

Patient Selection

  • Chronic migraine diagnosis confirmed (diary).
  • Failed ≥2 oral preventives (adequate dose/duration).
  • No contraindication: NMJ disorders (myasthenia, Lambert-Eaton), pregnancy, infection at sites.
  • Realistic expectations: reduction, not elimination; commitment to quarterly visits.

Insurance & Access

Prior auth requires documentation of chronic migraine + failed preventives. Patient assistance programs available. Combine with oral preventives/acute meds as needed.

Migraine - Related Articles